Iridex’s revised MicroPulse P3 transscleral laser therapy is a safe, non-incisional and effective way to reduce intraocular pressure (IOP), while leaving options open for future treatment. This intuitive, versatile and user friendly device has a new ergonomic design that allows a smoother movement during treatment.
MicroPulse P3 transscleral laser therapy can be delivered in the office or operating theatre in less than five minutes. Over 120,000 patients have been treated with this device in 60 countries with the following results:
- A success rate of 60% to 80%,1-17
- Reduces IOP reduction by 30% to 45%,1,3,6,9-15,17,18
- Durable for up to 72 months with three retreatments,19
- Reduces drug burden in eye drops and oral medications,1-4,6-13,18
- Revised probe improves ease of use, visualisation, fit, and coupling,
- Limits amount of immediate follow-up, and
- Lowers patient downtime.
Contact: Optimed (AUS) 1300 657 720
References:
- Zaarour K, et al. J Glaucoma 2019.
- Subramaniam K, et al. Cornea 2019.
- Nguyen AT, et al. Eur J Ophthalmol 2019.
- Barac R, et a. Romanian J Ophthalmol 2018.
- Sanchez FG, et al. Arch Soc Esp Oftalmol 2018.
- Lee JH, et al. J Glaucoma 2017.
- Sarrafpour S, et al. Ophthalmology Glaucoma 2019.
- Awoyesuku EA, et al. JAMMR 2019.
- Abdelrahman AM, et al. J Glaucoma 2018.
- Aquino MC, et al. Clin Exp Ophthalmol 2015.
- Jammal AA, et al. Arq Bras Oftalmol 2019.
- Tan A, et al. Clin Experiment Ophthalmol 2010.
- Williams AL, et al. J Glaucoma 2018.
- Varikuti VNV, et al. J Glaucoma 2019.
- Souissi S, et al. Eur J Ophthalmol 2019.
- Magacho L, et al. Lasers Med Sci 2019.
- Magacho L, et al. J Glaucoma 2019.
- Yelenskiy A, et al. J Glaucoma 2018.
- Aquino M, et al. European Glaucoma Society 2016.
